Regeneron Reports Strong Q1 Earnings Amid Eylea Sales Decline
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 02 2026
0mins
Source: Fool
- Strong Earnings: Regeneron reported Q1 revenue of $3.6 billion, a 19% year-over-year increase that surpassed analysts' expectations of $3.48 billion, while EPS was $6.75, down 7% year-over-year, but adjusted EPS rose 15% to $9.47, indicating resilience in profitability.
- Eylea Sales Decline: Total sales of Eylea fell 10% to $941 million, yet Eylea HD sales surged 52% to $468 million, suggesting that the company's strategic adjustments to counter competition may be effective.
- New Therapy Approval: The FDA granted approval for Otarmeni as the first gene therapy, which will be offered for free in the U.S., but Regeneron plans to charge traditional prices abroad, a strategy that could help safeguard the profitability of its overall portfolio.
- Ongoing R&D Investment: Regeneron expects to spend $6 billion on R&D in 2026, and despite the pressure from declining Eylea sales, the company maintains a gross margin of 76%, demonstrating its competitiveness and conservative capital management in the high-growth biotech sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy REGN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on REGN
Wall Street analysts forecast REGN stock price to rise
22 Analyst Rating
16 Buy
6 Hold
0 Sell
Moderate Buy
Current: 618.030
Low
637.00
Averages
808.50
High
1057
Current: 618.030
Low
637.00
Averages
808.50
High
1057
About REGN
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Lynozyfic, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Regeneron's Cemdisiran Marketing Applications Accepted by U.S. and European Regulators
- Drug Application Progress: Regeneron (REGN) and Alnylam Pharmaceuticals (ALNY) have had their marketing applications for the experimental therapy cemdisiran accepted by U.S. and European regulators, marking a significant advancement in treating myasthenia gravis.
- Priority Review Approval: The U.S. FDA has issued a priority review for cemdisiran's New Drug Application with a target action date in November, which will expedite the drug's market entry and is expected to significantly enhance Regeneron's competitive position.
- European Market Outlook: The European Medicines Agency has accepted the marketing authorization application for cemdisiran, with final approval from the European Commission anticipated in H2 2027, laying the groundwork for Regeneron's expansion in the European market.
- Clinical Trial Results: Based on 24-week data, Regeneron announced in August that the treatment arm testing cemdisiran as a single agent in adults with symptomatic myasthenia gravis met the primary goals of the NIMBLE trial, further validating the drug's efficacy and safety.
See More
Regeneron and Amgen's Promising Weight Loss Candidates
- Clinical Trial Progress: Regeneron plans to initiate phase 3 clinical trials for its weight-loss candidate olatorepatide this year, which demonstrated up to 19% weight loss in a 48-week study in China, indicating significant potential in the weight loss market; approval in the U.S. could further boost the company's revenue growth.
- Strong Financial Performance: Regeneron's revenue surged by 19% year-over-year to $3.6 billion in Q1, showcasing resilience despite biosimilar competition for Eylea, with sales of a new high-dose formulation growing rapidly, reflecting the company's adaptability in the biopharmaceutical sector.
- Amgen's Competitive Edge: Amgen is conducting phase 3 studies for its anti-obesity drug MariTide, which targets chronic weight management, type 2 diabetes, and cardiovascular outcomes; approval across multiple indications could pose a substantial challenge to market leaders, driving future revenue growth for the company.
- Dividend Appeal: Amgen has increased its dividends annually since 2011, currently offering a forward yield of 3%, significantly higher than the S&P 500 average, attracting long-term investors while providing additional income security for shareholders interested in weight-loss stocks.
See More
Emerging Stars in Weight Loss: Regeneron and Amgen
- Regeneron Clinical Progress: Regeneron plans to initiate phase 3 trials for its weight-loss candidate olatorepatide this year, which demonstrated up to 19% weight loss in a 48-week study in China, indicating strong potential in the weight-loss market; approval in the U.S. could significantly boost the company's growth.
- Strong Financial Performance: Regeneron's revenue surged 19% year-over-year to $3.6 billion in Q1, and despite facing biosimilar competition for Eylea, the sales growth of a new high-dose formulation reflects a solid financial foundation beyond weight-loss drugs.
- Amgen's Drug Development: Amgen is conducting phase 3 studies for its anti-obesity drug MariTide, which, if approved, will target chronic weight management and type 2 diabetes, potentially positioning it as a formidable competitor to Zepbound and expanding market share.
- Stable Dividend Yield: Amgen's revenue rose 6% year-over-year to $8.6 billion in Q1, and despite losing patent exclusivity for denosumab, strong sales from other products like Tezspire and Tepezza, along with consistent dividend increases since 2011, make it attractive for long-term investors.
See More
AbbVie Acquires Apogee Therapeutics for $10.9 Billion
- Acquisition Overview: AbbVie has agreed to acquire Apogee Therapeutics for $10.9 billion in cash, offering $135.11 per share, which represents a 49% premium over Apogee's Thursday closing price, marking AbbVie's largest acquisition in over five years and highlighting its strategic focus on dermatological treatments.
- Drug Development Prospects: Apogee's lead drug, zumilokibart, targets atopic dermatitis, a skin condition affecting over 200 million people globally, with plans to initiate a phase-three trial later this year, which, if successful, could provide AbbVie with a new revenue stream and enhance its competitive position in the dermatology market.
- Market Competition Analysis: Zumilokibart is positioned as a longer-acting alternative to Dupixent, which generated $17.8 billion in revenue last year, and AbbVie's acquisition will strengthen its position in the anti-inflammatory drug market, particularly for potential applications in various inflammatory diseases, including asthma.
- Industry Merger Trends: This acquisition occurs amid a broader wave of pharmaceutical M&A, with over $200 billion in healthcare acquisitions agreed upon this year, indicating AbbVie's commitment to expanding its product line and reflecting strong market demand for innovative therapies.
See More
AbbVie Launches $11 Billion Bid for Apogee Therapeutics
- Acquisition Bid: AbbVie is planning to acquire Apogee Therapeutics for approximately $10.9 billion, a price that is about 60% higher than Thursday's closing price, which could significantly enhance AbbVie's market share in the dermatology treatment sector.
- Market Reaction: Apogee's stock surged over 50% in pre-market trading, reflecting a positive market response to the deal, while AbbVie's stock remained relatively unchanged, indicating investor confidence in its long-term strategy.
- Drug Potential: Apogee's new drug, Zumilokibart, is expected to enter Phase 3 trials later this year, and if approved, it will compete against Regeneron's Dupixent, which generated $17.8 billion in revenue last year, showcasing the market potential of Apogee's drug.
- Industry Outlook: AbbVie's acquisition not only diversifies its product pipeline but also strengthens its competitive position in the rapidly evolving dermatology market by potentially integrating Apogee's innovative therapies, thereby solidifying its leadership in the industry.
See More
Cemdisiran Could Be First siRNA Approved for gMG Treatment
- FDA Priority Review: The FDA has accepted the NDA for Cemdisiran with a target action date in November 2026, potentially making it the first siRNA therapy for anti-AChR antibody-positive gMG patients, which could significantly enhance patient quality of life.
- European Regulatory Progress: A decision from the European Commission is anticipated in the second half of 2027, and if approved, Cemdisiran will offer subcutaneous dosing four times a year, improving patient adherence and treatment outcomes.
- Clinical Trial Support: The application is supported by data from the NIMBLE Phase 3 trial, one of the largest interventional gMG trials to date, demonstrating its potential to alleviate symptoms and possibly transform the treatment landscape for gMG.
- Global Market Outlook: With an estimated prevalence of 150 to 200 cases per million worldwide and approximately 85,000 affected individuals in the U.S., the successful launch of Cemdisiran could position Regeneron as a leader in this market, driving further growth for the company.
See More
Regeneron's Cemdisiran Marketing Applications Accepted by U.S. and European Regulators
- Drug Application Progress: Regeneron (REGN) and Alnylam Pharmaceuticals (ALNY) have had their marketing applications for the experimental therapy cemdisiran accepted by U.S. and European regulators, marking a significant advancement in treating myasthenia gravis.
- Priority Review Approval: The U.S. FDA has issued a priority review for cemdisiran's New Drug Application with a target action date in November, which will expedite the drug's market entry and is expected to significantly enhance Regeneron's competitive position.
- European Market Outlook: The European Medicines Agency has accepted the marketing authorization application for cemdisiran, with final approval from the European Commission anticipated in H2 2027, laying the groundwork for Regeneron's expansion in the European market.
- Clinical Trial Results: Based on 24-week data, Regeneron announced in August that the treatment arm testing cemdisiran as a single agent in adults with symptomatic myasthenia gravis met the primary goals of the NIMBLE trial, further validating the drug's efficacy and safety.
See More
Regeneron and Amgen's Promising Weight Loss Candidates
- Clinical Trial Progress: Regeneron plans to initiate phase 3 clinical trials for its weight-loss candidate olatorepatide this year, which demonstrated up to 19% weight loss in a 48-week study in China, indicating significant potential in the weight loss market; approval in the U.S. could further boost the company's revenue growth.
- Strong Financial Performance: Regeneron's revenue surged by 19% year-over-year to $3.6 billion in Q1, showcasing resilience despite biosimilar competition for Eylea, with sales of a new high-dose formulation growing rapidly, reflecting the company's adaptability in the biopharmaceutical sector.
- Amgen's Competitive Edge: Amgen is conducting phase 3 studies for its anti-obesity drug MariTide, which targets chronic weight management, type 2 diabetes, and cardiovascular outcomes; approval across multiple indications could pose a substantial challenge to market leaders, driving future revenue growth for the company.
- Dividend Appeal: Amgen has increased its dividends annually since 2011, currently offering a forward yield of 3%, significantly higher than the S&P 500 average, attracting long-term investors while providing additional income security for shareholders interested in weight-loss stocks.
See More
Emerging Stars in Weight Loss: Regeneron and Amgen
- Regeneron Clinical Progress: Regeneron plans to initiate phase 3 trials for its weight-loss candidate olatorepatide this year, which demonstrated up to 19% weight loss in a 48-week study in China, indicating strong potential in the weight-loss market; approval in the U.S. could significantly boost the company's growth.
- Strong Financial Performance: Regeneron's revenue surged 19% year-over-year to $3.6 billion in Q1, and despite facing biosimilar competition for Eylea, the sales growth of a new high-dose formulation reflects a solid financial foundation beyond weight-loss drugs.
- Amgen's Drug Development: Amgen is conducting phase 3 studies for its anti-obesity drug MariTide, which, if approved, will target chronic weight management and type 2 diabetes, potentially positioning it as a formidable competitor to Zepbound and expanding market share.
- Stable Dividend Yield: Amgen's revenue rose 6% year-over-year to $8.6 billion in Q1, and despite losing patent exclusivity for denosumab, strong sales from other products like Tezspire and Tepezza, along with consistent dividend increases since 2011, make it attractive for long-term investors.
See More
AbbVie Acquires Apogee Therapeutics for $10.9 Billion
- Acquisition Overview: AbbVie has agreed to acquire Apogee Therapeutics for $10.9 billion in cash, offering $135.11 per share, which represents a 49% premium over Apogee's Thursday closing price, marking AbbVie's largest acquisition in over five years and highlighting its strategic focus on dermatological treatments.
- Drug Development Prospects: Apogee's lead drug, zumilokibart, targets atopic dermatitis, a skin condition affecting over 200 million people globally, with plans to initiate a phase-three trial later this year, which, if successful, could provide AbbVie with a new revenue stream and enhance its competitive position in the dermatology market.
- Market Competition Analysis: Zumilokibart is positioned as a longer-acting alternative to Dupixent, which generated $17.8 billion in revenue last year, and AbbVie's acquisition will strengthen its position in the anti-inflammatory drug market, particularly for potential applications in various inflammatory diseases, including asthma.
- Industry Merger Trends: This acquisition occurs amid a broader wave of pharmaceutical M&A, with over $200 billion in healthcare acquisitions agreed upon this year, indicating AbbVie's commitment to expanding its product line and reflecting strong market demand for innovative therapies.
See More
AbbVie Launches $11 Billion Bid for Apogee Therapeutics
- Acquisition Bid: AbbVie is planning to acquire Apogee Therapeutics for approximately $10.9 billion, a price that is about 60% higher than Thursday's closing price, which could significantly enhance AbbVie's market share in the dermatology treatment sector.
- Market Reaction: Apogee's stock surged over 50% in pre-market trading, reflecting a positive market response to the deal, while AbbVie's stock remained relatively unchanged, indicating investor confidence in its long-term strategy.
- Drug Potential: Apogee's new drug, Zumilokibart, is expected to enter Phase 3 trials later this year, and if approved, it will compete against Regeneron's Dupixent, which generated $17.8 billion in revenue last year, showcasing the market potential of Apogee's drug.
- Industry Outlook: AbbVie's acquisition not only diversifies its product pipeline but also strengthens its competitive position in the rapidly evolving dermatology market by potentially integrating Apogee's innovative therapies, thereby solidifying its leadership in the industry.
See More
Cemdisiran Could Be First siRNA Approved for gMG Treatment
- FDA Priority Review: The FDA has accepted the NDA for Cemdisiran with a target action date in November 2026, potentially making it the first siRNA therapy for anti-AChR antibody-positive gMG patients, which could significantly enhance patient quality of life.
- European Regulatory Progress: A decision from the European Commission is anticipated in the second half of 2027, and if approved, Cemdisiran will offer subcutaneous dosing four times a year, improving patient adherence and treatment outcomes.
- Clinical Trial Support: The application is supported by data from the NIMBLE Phase 3 trial, one of the largest interventional gMG trials to date, demonstrating its potential to alleviate symptoms and possibly transform the treatment landscape for gMG.
- Global Market Outlook: With an estimated prevalence of 150 to 200 cases per million worldwide and approximately 85,000 affected individuals in the U.S., the successful launch of Cemdisiran could position Regeneron as a leader in this market, driving further growth for the company.
See More
